IVIG Therapy Guidelines for Hypogammaglobulinemia

Indications for IVIG Therapy

The American College of Physicians recommends IVIG therapy for patients with severely low IgG levels, history of recurrent infections, and immunocompromised status, such as post-transplant patients, with an IgG level of less than 400-500 mg/dL 1, 2
IVIG is recommended for transplant recipients with severe hypogammaglobulinemia (IgG < 400 mg/dL) within the first 100 days after transplant, according to the Centers for Disease Control and Prevention (CDC) guidelines 3

The IVIG regimen should be optimized to maintain trough IgG levels above 400-500 mg/dL, with a frequency of every 4 weeks, as recommended by the National Comprehensive Cancer Network (NCCN) 1
The dose of IVIG should be individualized to maintain trough IgG levels above 400-500 mg/dL, with a current dose of 40g appearing appropriate, according to the Haematologica guidelines 1, 2
Trough IgG levels should be checked approximately every 2 weeks initially to ensure adequate replacement, as recommended by the MMWR Recommendations and Reports 3

Regular IgG monitoring is essential, with trough IgG levels checked before each infusion, and target trough levels above 400-500 mg/dL, according to the CDC guidelines 3, 2
Infection surveillance is crucial, with monitoring for signs of new infections and tracking frequency and severity of infections, as recommended by the NCCN guidelines 1

Transplant recipients may require higher and more frequent IVIG doses due to shorter half-life (1-10 days vs 18-23 days in healthy adults), according to the CDC guidelines 3
Infections can accelerate IgG catabolism, requiring dose adjustments, as recommended by the MMWR Recommendations and Reports 3